• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    Jan 19, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    PIIS014067360961117X.pdf
    Size:
    176.3Kb
    Format:
    PDF
    Download
    Authors
    Priotto, G
    Kasparian, S
    Mutombo, W
    Ngouama, D
    Ghorashian, S
    Arnold, U
    Ghabri, S
    Baudin, E
    Buard, V
    Kazadi-Kyanza, S
    Ilunga, M
    Mutangala, W
    Pohlig, G
    Schmid, C
    Karunakara, U
    Torreele, E
    Kande, V
    Show allShow less
    Affiliation
    Epicentre, Paris, France;Ministry of Health, Republic of the Congo;Médecins Sans Frontières, Holland and Belgium;Swiss Tropical Institute, Basel, Switzerland;Drugs for Neglected Diseases Initiative, Geneva, Switzerland
    Issue Date
    2009-07-04
    
    Metadata
    Show full item record
    Journal
    Lancet
    Abstract
    Background Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineffective, or impractical. We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen. Methods A multicentre, randomised, open-label, active control, phase III, non-inferiority trial was done at four HAT treatment centres in the Republic of the Congo and the Democratic Republic of the Congo. Patients aged 15 years or older with confirmed second-stage T b gambiense infection were randomly assigned by computer-generated randomisation sequence to receive intravenous eflornithine (400 mg/kg per day, every 6 h; n=144) for 14 days or intravenous eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral nifurtimox (15 mg/kg per day, every 8 h) for 10 days (NECT; n=143). The primary endpoint was cure (defined as absence of trypanosomes in body fluids and a leucocyte count ≤20 cells per μL) 18 months after treatment. Efficacy analyses were done in the intention-to-treat (ITT), modified ITT, and per-protocol (PP) populations. The non-inferiority margin for the difference in cure rates was defined as 10%. This study is registered with ClinicalTrials.gov, number NCT00146627. Findings One patient from the eflornithine group absconded after receiving the first dose, without any type of assessment done, and was excluded from all analyses. In the ITT population, 131 (91·6%) of 143 patients assigned to eflornithine and 138 (96·5%) of 143 patients assigned to NECT were cured at 18 months (difference −4·9%, one-sided 95% CI −0·3; p<0·0001). In the PP population, 122 (91·7%) of 133 patients in the eflornithine group and 129 (97·7%) of 132 in the NECT group were cured at 18 months (difference −6·0%, one-sided 95% CI −1·5; p<0·0001). Drug-related adverse events were frequent in both groups; 41 (28·7%) patients in the eflornithine group and 20 (14·0%) in the NECT group had major (grade 3 or 4) reactions, which resulted in temporary treatment interruption in nine and one patients, respectively. The most common major adverse events were fever (n=18), seizures (n=6), and infections (n=5) in the eflornithine group, and fever (n=7), seizures (n=6), and confusion (n=2) in the NECT group. There were four deaths, which were regarded as related to study drug (eflornithine, n=3; NECT, n=1). Interpretation The efficacy of NECT is non-inferior to that of eflornithine monotherapy. Since this combination treatment also presents safety advantages, is easier to administer (ie, infusion every 12 h for 7 days vs every 6 h for 14 days), and potentially protective against the emergence of resistant parasites, it is suitable for first-line use in HAT control programmes. Funding Médecins Sans Frontières (Dutch section), Médecins Sans Frontières International, and the Drugs for Neglected Diseases Initiative.
    Publisher
    Elsevier
    URI
    http://hdl.handle.net/10144/72797
    DOI
    10.1016/S0140-6736(09)61117-X
    Additional Links
    http://www.lancet.com/journals/lancet/article/PIIS0140-6736(09)61117-X/fulltext
    Type
    Article
    Language
    en
    ISSN
    01406736
    1474547X
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0140-6736(09)61117-X
    Scopus Count
    Collections
    Trypanosomiasis/Sleeping Sickness

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.